Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Three-Year EU MDR Transition Period? More Like 12-18 Months

Executive Summary

So, you think you have nearly three years to comply with the EU's Medical Device Regulation and five years with the IVD Regulation. Not so. The clock has started ticking and industry has reason to be concerned.

You may also be interested in...



EU Commission May Be Swamped As Notified Bodies Race To Start Line

It is nearly six months since the EU's Medical Device and IVD Regulations entered into force. In 10 days' time, on Nov. 26, notified bodies can apply to be designated under the new rules. More are ready than expected. Can the European Commission cope?

Notified Body Codes: EU Commission Needs To Act Fast

New codes that indicate the scope of notified bodies under the new EU regulations are nearly ready. Will the first implementing act be out on November 26?

Harmonization On The Mind: UK MHRA Wants Major Role In Global Regulation

Regardless of the path that the UK-EU Brexit negotiations take, the UK MHRA and the bulk of the local medtech industry are very clear on one thing: The need to retain access to the nascent EU Medical Device and IVD Regulations – and with it, EU reciprocity on device regulation. Any alternative approach is likely to engender unfathomable difficulties and disadvantage for the homegrown UK medtech industry, stakeholders say.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT121623

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel